From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …

Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

The incidence of chronic myeloid leukaemia (CML) ranges between 10 and 15
cases/106/year without any major geographic or ethnic differences [1]. The median age at …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …

Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …

Background Nilotinib has shown greater efficacy than imatinib in patients with newly
diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic …

This study examines the prognostic significance of early molecular response using an
expanded dataset in chronic myeloid leukemia patients enrolled in the International …

An international basis for comparison of BCR-ABL mRNA levels is required for the common
interpretation of data derived from individual laboratories. This will aid clinical decisions for …

Abstract Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has
advanced to a stage where many patients achieve very low or undetectable levels of …